drugset

drugset / Trial / NCT03551288

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

NCT03551288 ↗

Phase 1 Completed 28 enrolled Suven Life Sciences Limited

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

Timeline

Start: 2018-05-22
Primary completion: 2018-07-10
Completion: 2018-07-16

Publications

Nirogi R, Benade V, Goyal VK, Pandey SK, Mohammed AR, Shinde A, Dogiparti D, Ravula J, Jetta S, Palacharla VRC. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (alpha4beta2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects. Clin Drug Investig. 2022 Sep;42(9):747-762. doi: 10.1007/s40261-022-01189-9. Epub 2022 Aug 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ropanicant	Small molecule	30 mg	Oral

Indications